Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2021 | Original Article

Why bother with alpha particles?

Authors: A. Paden King, Frank I. Lin, Freddy E. Escorcia

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2021

Abstract

The approval of ²²³RaCl₂ for cancer therapy in 2013 has heralded a resurgence of interest in the development of α-particle emitting radiopharmaceuticals. In the last decade, over a dozen α-emitting radiopharmaceuticals have entered clinical trials, spawned by strong preclinical studies. In this article, we explore the potential role of α-particle therapy in cancer treatment. We begin by providing a background for the basic principles of therapy with α-emitters, and we explore recent breakthroughs in therapy with α-emitting radionuclides, including conjugates with small molecules and antibodies. Finally, we discuss some outstanding challenges to the clinical adoption of α-therapies and potential strategies to address them.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity ¹³¹I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623–30. https://doi.org/10.2967/jnumed.118.217463.CrossRefPubMedPubMedCentral

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. https://doi.org/10.1056/NEJMoa1213755.CrossRefPubMed

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;NEJMoa2107322.

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608. https://doi.org/10.1038/s41573-020-0073-9.CrossRefPubMed

Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24. https://doi.org/10.3389/fmolb.2014.00024.CrossRefPubMedPubMedCentral

Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009;69:383–92. https://doi.org/10.1158/0008-5472.CAN-07-6871.CrossRefPubMed

Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res. 1998;150:263–8.CrossRef

Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019;4:27. https://doi.org/10.1186/s41181-019-0075-2.CrossRefPubMedPubMedCentral

10.

Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res. 2013;19:530–7. https://doi.org/10.1158/1078-0432.CCR-12-0298.CrossRefPubMed

11.

Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol. 1994;65:7–17. https://doi.org/10.1080/09553009414550021.CrossRefPubMed

12.

Sutherland BM, Bennett PV, Sidorkina O, Laval J. Clustered damages and total lesions induced in DNA by ionizing radiation: oxidized bases and strand breaks. Biochemistry. 2000;39:8026–31. https://doi.org/10.1021/bi9927989.CrossRefPubMed

13.

Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 2013;19:200–7. https://doi.org/10.1097/PPO.0b013e318292e4e3.CrossRefPubMedPubMedCentral

14.

Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Sublethal exposure to alpha radiation (²²³Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget. 2016;7:86937–47. https://doi.org/10.18632/oncotarget.13520.CrossRefPubMedPubMedCentral

15.

Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol Hematol. 2018;123:7–20. https://doi.org/10.1016/j.critrevonc.2018.01.001.CrossRefPubMed

16.

Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood. 2012;120:2087–97. https://doi.org/10.1182/blood-2012-01-404509.CrossRefPubMedPubMedCentral

17.

Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME. Cellular and genetic determinants of the sensitivity of cancer to alpha-particle irradiation. Cancer Res. 2019;79:5640–51. https://doi.org/10.1158/0008-5472.CAN-19-0859.CrossRefPubMedPubMedCentral

18.

Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with ²²⁵Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to ¹⁷⁷Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934–46. https://doi.org/10.1007/s00259-019-04567-2.CrossRefPubMed

19.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. ²²⁵Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4. https://doi.org/10.2967/jnumed.116.178673.CrossRefPubMed

20.

Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10:9364–77. https://doi.org/10.7150/thno.48107.CrossRefPubMedPubMedCentral

21.

Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res. 2012;751:158–246. https://doi.org/10.1016/j.mrrev.2012.06.002.CrossRefPubMed

22.

Bannik K, Madas B, Jarzombek M, Sutter A, Siemeister G, Mumberg D, et al. Radiobiological effects of the alpha emitter Ra-223 on tumor cells. Sci Rep. 2019;9:18489. https://doi.org/10.1038/s41598-019-54884-7.CrossRefPubMedPubMedCentral

23.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. ²¹²Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther. 2012;11:639–48. https://doi.org/10.1158/1535-7163.MCT-11-0671.CrossRefPubMedPubMedCentral

24.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int J Radiat Oncol Biol Phys. 2013;85:1119–26. https://doi.org/10.1016/j.ijrobp.2012.09.015.CrossRefPubMed

25.

Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, et al. ^203/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Curr Med Chem. 2020;27:7003–31. https://doi.org/10.2174/0929867327999200727190423.CrossRefPubMed

26.

Larsson E, Brolin G, Cleton A, Ohlsson T, Linden O, Hindorf C. Feasibility of thorium-227/radium-223 gamma-camera imaging during radionuclide therapy. Cancer Biother Radiopharm. 2020;35:540–8. https://doi.org/10.1089/cbr.2019.3516.CrossRefPubMed

27.

Usmani S, Rasheed R, Al Kandari F, Marafi F, Naqvi SAR. ²²⁵Ac Prostate-specific membrane antigen posttherapy alpha imaging: comparing 2 and 3 photopeaks. Clin Nucl Med. 2019;44:401–3. https://doi.org/10.1097/RLU.0000000000002525.CrossRefPubMed

28.

Abou DS, Rittenbach A, Tomlinson RE, Finley PA, Tsui B, Simons BW, et al. Preclinical single photon emission computed tomography of alpha particle-emitting radium-223. Cancer Biother Radiopharm. 2020;35:520–9. https://doi.org/10.1089/cbr.2019.3308.CrossRefPubMedPubMedCentral

29.

Phelps TE, Roy J, Green MV, Seidel J, Baidoo KE, Adler S, et al. Sodium fluoride-18 and radium-223 dichloride uptake colocalize in osteoblastic mouse xenograft tumors. Cancer Biother Radiopharm. 2021;36:133–42. https://doi.org/10.1089/cbr.2020.4068.CrossRefPubMed

30.

Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, et al. The potential of ²²³Ra and ¹⁸F-fluoride imaging to predict bone lesion response to treatment with ²²³Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1832–44. https://doi.org/10.1007/s00259-017-3744-y.CrossRefPubMedPubMedCentral

31.

Moiseeva AN, Aliev RA, Unezhev VN, Zagryadskiy VA, Latushkin ST, Aksenov NV, et al. Cross section measurements of ¹⁵¹Eu((3)He,5n) reaction: new opportunities for medical alpha emitter ¹⁴⁹Tb production. Sci Rep. 2020;10:508. https://doi.org/10.1038/s41598-020-57436-6.CrossRefPubMedPubMedCentral

32.

Dronsfield A, Ellis P. Radium – a key element in early cancer treatment. Educ Chem. 2011:56–9. https://www.rsc.org/images/Dronsfield_tcm18-200827.pdf.

33.

Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822–7. https://doi.org/10.1158/1078-0432.CCR-13-1896.CrossRefPubMed

34.

Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406. https://doi.org/10.1016/S1470-2045(14)70474-7.CrossRefPubMed

35.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019;114:107–16. https://doi.org/10.1016/j.ejca.2019.04.007.CrossRefPubMedPubMedCentral

36.

Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, et al. A phase II randomized trial of radium-223 dichloride and SABR versus SABR for oligometastatic prostate cancers (RAVENS). BMC Cancer. 2020;20:492. https://doi.org/10.1186/s12885-020-07000-2.CrossRefPubMedPubMedCentral

37.

Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745–56. https://doi.org/10.1038/s41585-019-0251-x.CrossRefPubMedPubMedCentral

38.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408–19. https://doi.org/10.1016/S1470-2045(18)30860-X.CrossRefPubMed

39.

Abou DS, Thiele NA, Gutsche NT, Villmer A, Zhang H, Woods JJ, Baidoo KE, Escorcia FE, Wilson JJ, Thorek DL. Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand. Chem Sci. 2021;12:3733–42. https://doi.org/10.1039/D0SC06867E.CrossRefPubMedPubMedCentral

40.

Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011;4:306–20. https://doi.org/10.2174/1874471011104040306.CrossRefPubMedPubMedCentral

41.

Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012;33:573–90. https://doi.org/10.1007/s13277-011-0286-y.CrossRefPubMed

42.

Guerra Liberal FDC, O’Sullivan JM, McMahon SJ, Prise KM. Targeted alpha therapy: current clinical applications. Cancer Biother Radiopharm. 2020;35:404–17. https://doi.org/10.1089/cbr.2020.3576.t.CrossRefPubMed

43.

McDevitt MR, Sgouros G, Sofou S. Targeted and nontargeted alpha-particle therapies. Annu Rev Biomed Eng. 2018;20:73–93. https://doi.org/10.1146/annurev-bioeng-062117-120931.CrossRefPubMedPubMedCentral

44.

Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S-204S.PubMed

45.

Escorcia FE, Houghton JL, Abdel-Atti D, Pereira PR, Cho A, Gutsche NT, et al. ImmunoPET predicts response to met-targeted radioligand therapy in models of pancreatic cancer resistant to Met kinase inhibitors. Theranostics. 2020;10:151–65. https://doi.org/10.7150/thno.37098.CrossRefPubMedPubMedCentral

46.

Navalkissoor S, Grossman A. Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy. Neuroendocrinology. 2019;108:256–64. https://doi.org/10.1159/000494760.CrossRefPubMed

47.

Kunikowska J, Krolicki L. Targeted alpha-emitter therapy of neuroendocrine tumors. Semin Nucl Med. 2020;50:171–6. https://doi.org/10.1053/j.semnuclmed.2019.11.003.CrossRefPubMed

48.

Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, et al. Preclinical evaluation of the alpha-particle generator nuclide ²²⁵Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555–61. https://doi.org/10.1158/1078-0432.CCR-07-4647.CrossRefPubMed

49.

Bal C, Yadav M, Ballal S, Tripathi M. Safety and therapeutic efficacy of ²²⁵Ac-DOTATATE targeted alpha therapy in metastatic gastroenteropancreatic neuroendocrine tumors stable or refractory to ¹⁷⁷Lu-DOTATATE PRRT. J Nucl Med. 2020;61:416.

50.

Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19. https://doi.org/10.1007/s00259-014-2857-9.CrossRefPubMedPubMedCentral

51.

Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ. Preclinical Investigation of ²¹²Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model. Mol Cancer Ther. 2019;18:1012–21. https://doi.org/10.1158/1535-7163.MCT-18-1103.CrossRefPubMed

52.

Delpassand E, Tworowska I, Shanoon F, Nunez R, Flores L II, Muzammil A, et al. First clinical experience using targeted alpha-emitter therapy with ²¹²Pb-DOTAMTATE (AlphaMedix^TM in patients with SSTR(+) neuroendocrine tumors. J Nucl Med. 2019;60:559.

53.

Filippi L, Chiaravalloti A, Schillaci O, Bagni O. The potential of PSMA-targeted alpha therapy in the management of prostate cancer. Expert Rev Anticancer Ther. 2020;20:823–9. https://doi.org/10.1080/14737140.2020.1814151.CrossRefPubMed

54.

Dos Santos JC, Schafer M, Bauder-Wust U, Lehnert W, Leotta K, Morgenstern A, et al. Development and dosimetry of ²⁰³Pb/²¹²Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46:1081–91. https://doi.org/10.1007/s00259-018-4220-z.CrossRefPubMedPubMedCentral

55.

Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. ²¹³Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100. https://doi.org/10.1007/s00259-017-3657-9.CrossRefPubMedPubMedCentral

56.

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med. 2019;7:105. https://doi.org/10.21037/atm.2019.01.42.CrossRefPubMedPubMedCentral

57.

Rizzieri D. Zevalin((R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016;105:5–17. https://doi.org/10.1016/j.critrevonc.2016.07.008.CrossRefPubMed

58.

Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med. 2011;52:830–8. https://doi.org/10.2967/jnumed.110.085589.CrossRefPubMed

59.

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–28. https://doi.org/10.1200/JCO.2001.19.19.3918.CrossRefPubMed

60.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–64. https://doi.org/10.1200/JCO.2008.17.2015.CrossRefPubMed

61.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: ²¹³Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935–46.PubMed

62.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–9.CrossRef

63.

Friesen C, Roscher M, Hormann I, Leib O, Marx S, Moreno J, et al. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur J Cancer. 2013;49:2542–54. https://doi.org/10.1016/j.ejca.2013.04.008.CrossRefPubMed

64.

Jurcic JG. Clinical studies with bismuth-213 and actinium-225 for hematologic malignancies. Curr Radiopharm. 2018;11:192–9. https://doi.org/10.2174/1874471011666180525102814.CrossRefPubMed

65.

Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, Chanel S, Frattini MG, et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (²²⁵Ac)-HuM195 (Anti-CD33) in acute myeloid leukemia (AML). Blood. 2007;110:910. https://doi.org/10.1182/blood.V110.11.910.910.CrossRef

66.

Jurcic JG, Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, Chanel SM, Zikaras K, Frattini MG, Maslak PM, Cicic D, Larson SM, Scheinberg DA. Targeted alpha-particle nano-generator actinium-225 (²²⁵Ac)-lintuzumab (anti-CD33) in acute myeloid leukemia (AML), clinical lymphoma myeloma and leukemia. 2013;13:S379-S80. https://doi.org/10.1016/j.clml.2013.07.088.

67.

Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, Apostolidis C, et al. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy. 2011;3:1041–50. https://doi.org/10.2217/imt.11.97.CrossRefPubMed

68.

Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B, et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45:1364–71. https://doi.org/10.1007/s00259-018-4003-6.CrossRefPubMed

69.

Lindegren S, Albertsson P, Back T, Jensen H, Palm S, Aneheim E. Realizing clinical trials with astatine-211: the chemistry infrastructure. Cancer Biother Radiopharm. 2020;35:425–36. https://doi.org/10.1089/cbr.2019.3055.CrossRefPubMedPubMedCentral

70.

Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting ²¹¹At: treatment of recurrent brain tumor patients with ²¹¹At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30–8. https://doi.org/10.2967/jnumed.107.046938.CrossRefPubMed

71.

Hallqvist A, Bergmark K, Back T, Andersson H, Dahm-Kahler P, Johansson M, et al. Intraperitoneal alpha-emitting radioimmunotherapy with ²¹¹At in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations. J Nucl Med. 2019;60:1073–9. https://doi.org/10.2967/jnumed.118.220384.CrossRefPubMedPubMedCentral

72.

Frantellizzi V, Cosma L, Brunotti G, Pani A, Spanu A, Nuvoli S, et al. Targeted alpha therapy with thorium-227. Cancer Biother Radiopharm. 2020;35:437–45. https://doi.org/10.1089/cbr.2019.3105.CrossRefPubMed

73.

Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S, et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res. 2020;26:1985–96. https://doi.org/10.1158/1078-0432.CCR-19-2268.CrossRefPubMed

74.

Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, et al. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clin Cancer Res. 2019;25:4723–34. https://doi.org/10.1158/1078-0432.CCR-18-3476.CrossRefPubMed

75.

Verhoeven M, Seimbille Y, Dalm SU. Therapeutic applications of pretargeting. Pharmaceutics. 2019;11. https://doi.org/10.3390/pharmaceutics11090434.

76.

Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125:2561–9. https://doi.org/10.1002/cncr.32072.CrossRefPubMed

77.

Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a ²¹²Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20:557–68. https://doi.org/10.1089/cbr.2005.20.557.CrossRefPubMed

78.

Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of ²¹²Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12–7. https://doi.org/10.1089/cbr.2013.1531.CrossRefPubMedPubMedCentral

79.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and outcome measures of first-in-human intraperitoneal alpha radioimmunotherapy with ²¹²Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41:716–21. https://doi.org/10.1097/COC.0000000000000353.CrossRefPubMed

80.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, et al. Safety and efficacy of targeted alpha therapy with ²¹³Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46:614–22. https://doi.org/10.1007/s00259-018-4225-7.CrossRefPubMed

81.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with ²¹³Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018;45:1636–44. https://doi.org/10.1007/s00259-018-4015-2.CrossRefPubMedPubMedCentral

82.

Zaheer J, Kim H, Lee YJ, Kim JS, Lim SM. Combination radioimmunotherapy strategies for solid tumors. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20225579.

83.

Ahmad SS, Crittenden MR, Tran PT, Kluetz PG, Blumenthal GM, Bulbeck H, et al. Clinical development of novel drug-radiotherapy combinations. Clin Cancer Res. 2019;25:1455–61. https://doi.org/10.1158/1078-0432.CCR-18-2466.CrossRefPubMed

84.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. ²¹²Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. Br J Cancer. 2013;108:2013–20. https://doi.org/10.1038/bjc.2013.189.CrossRefPubMedPubMedCentral

85.

Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted alpha-particle radiation. Cancer Biother Radiopharm. 2013;28:441–9. https://doi.org/10.1089/cbr.2012.1423.CrossRefPubMedPubMedCentral

86.

Cesaire M, Thariat J, Candeias SM, Stefan D, Saintigny Y, Chevalier F. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19123793.

87.

Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, et al. Development of targeted alpha particle therapy for solid tumors. Molecules. 2019;24. https://doi.org/10.3390/molecules24234314.

88.

Anderson PM, Scott J, Parsai S, Zahler S, Worley S, Shrikanthan S, et al. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open. 2020;5. https://doi.org/10.1136/esmoopen-2019-000635.

89.

Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, et al. Leveraging bioorthogonal click chemistry to improve ²²⁵Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25:868–80. https://doi.org/10.1158/1078-0432.CCR-18-1650.CrossRefPubMed

90.

Patra M, Zarschler K, Pietzsch HJ, Stephan H, Gasser G. New insights into the pretargeting approach to image and treat tumours. Chem Soc Rev. 2016;45:6415–31. https://doi.org/10.1039/c5cs00784d.CrossRefPubMed

91.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004;104:227–36. https://doi.org/10.1182/blood-2003-09-3284.CrossRefPubMed

92.

Muller C, Vermeulen C, Koster U, Johnston K, Turler A, Schibli R, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. 2017;1:5. https://doi.org/10.1186/s41181-016-0008-2.CrossRefPubMed

93.

St James S, Bednarz B, Benedict S, Buchsbaum JC, Dewaraja Y, Frey E, et al. Current status of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys. 2021;109:891–901. https://doi.org/10.1016/j.ijrobp.2020.08.035.CrossRefPubMed

Title: Why bother with alpha particles?
Authors: A. Paden King
Frank I. Lin
Freddy E. Escorcia
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05431-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Why bother with alpha particles?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Imaging of the glioma microenvironment by TSPO PET

TSPO imaging in animal models of brain diseases

Cyclotron production of 225Ac from an electroplated 226Ra target

Contribution of TSPO imaging in the understanding of the state of gliosis in substance use disorders

Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box

Positive [18F]fluoroethyltyrosine PET/MRI in suspected recurrence of growth hormone–producing pituitary adenoma in a paediatric patient